The new conjugate vaccine MCV4 promises longer duration of immunity and, perhaps, greater clinical efficacy than the polysaccharide vaccine MPSV4. Questions remain about booster doses, vaccinating young children, and safety.
Amanda F. Dempsey, MD, PHD, MPH
Advertisement
Articles by Amanda F. Dempsey, MD, PHD, MPH
Advertisement
Latest Updated Articles
- A new day in preventing meningococcal disease: Sizing up the available vaccines
Published: October 1st 2006 | Updated:
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Tapinarof cream, 1% (VTAMA) shows early improvements in pediatric atopic dermatitis
2
Study: Child maltreatment rates declined overall, but disparities persisted across sex and race
3
Neurodevelopmental disorder risks not increased by prenatal acetaminophen use
4
